Antiviral TRIMs: Friend or foe in autoimmune and autoinflammatory disease?

Nature Reviews Immunology

Volumn 11, Issue 9, 2011, Pages 617-625

  Jefferies, Caroline ^a   Wynne, Claire ^a   Higgs, Rowan ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; INFLAMMASOME; INTERFERON; PEPTIDES AND PROTEINS; TRIPARTITE MOTIF CONTAINING PROTEIN; TRIPARTITE MOTIF CONTAINING PROTEIN 16; TRIPARTITE MOTIF CONTAINING PROTEIN 19; TRIPARTITE MOTIF CONTAINING PROTEIN 20; TRIPARTITE MOTIF CONTAINING PROTEIN 21; TRIPARTITE MOTIF CONTAINING PROTEIN 23; TRIPARTITE MOTIF CONTAINING PROTEIN 25; TRIPARTITE MOTIF CONTAINING PROTEIN 27; TRIPARTITE MOTIF CONTAINING PROTEIN 28; TRIPARTITE MOTIF CONTAINING PROTEIN 33; TRIPARTITE MOTIF CONTAINING PROTEIN 40; TRIPARTITE MOTIF CONTAINING PROTEIN 56; TRIPARTITE MOTIF CONTAINING PROTEIN 5ALPHA; TRIPARTITE MOTIF CONTAINING PROTEIN 68; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ANTIVIRAL ACTIVITY; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; CARRIER PROTEINS; DNA-BINDING PROTEINS; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; INFLAMMASOMES; INTERFERONS; MICE; REPRESSOR PROTEINS; RIBONUCLEOPROTEINS; RING FINGER DOMAINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; UBIQUITIN-PROTEIN LIGASES; VIRUSES;

EID: 80052101292     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3043     Document Type: Review

References (104)

1. Ozato, K., Shin, D. M., Chang, T. H. & Morse, H. C. TRIM family proteins and their emerging roles in innate immunity. Nature Rev. Immunol. 8, 849-860 (2008).
2. Stremlau, M. et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427, 848-853 (2004). (Pubitemid 38297747)
3. Gao, B., Duan, Z., Xu, W. & Xiong, S. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology 50, 424-433 (2009).
4. Rowe, H. M. et al. KAP1 controls endogenous retroviruses in embryonic stem cells. Nature 463, 237-240 (2010).
5. McNab, F. W., Rajsbaum, R., Stoye, J. P. & O'Garra, A. Tripartite-motif proteins and innate immune regulation. Curr. Opin. Immunol. 23, 46-56 (2011).
6. Koffler, D., Carr, R., Agnello, V., Thoburn, R. & Kunkel, H. G. Antibodies to polynucleotides in human sera: antigenic specificity and relation to disease. J. Exp. Med. 134, 294-312 (1971).
7. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006). (Pubitemid 43372104)
8. Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nature Immunol. 11, 897-904 (2010).
9. Rehaume, L. M., Jouault, T. & Chamaillard, M. Lessons from the inflammasome: a molecular sentry linking Candida and Crohn's disease. Trends Immunol. 31, 171-175 (2010).
10. Schroder, K., Zhou, R. & Tschopp, J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 327, 296-300 (2010).
11. Banchereau, J. & Pascual, V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25, 383-392 (2006). (Pubitemid 44354221)
12. Gilliet, M., Cao, W. & Liu, Y. J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nature Rev. Immunol. 8, 594-606 (2008).
13. Kyogoku, C. & Tsuchiya, N. A compass that points to lupus: genetic studies on type I interferon pathway. Genes Immun. 8, 445-455 (2007). (Pubitemid 47365611)
14. Barbalat, R., Ewald, S. E., Mouchess, M. L. & Barton, G. M. Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29, 185-214 (2011).
15. Lau, C. M. et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202, 1171-1177 (2005). (Pubitemid 41586947)
16. Leadbetter, E. A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603-607 (2002). (Pubitemid 34406754)
17. Laragione, T., Brenner, M., Li, W. & Gulko, P. S. Cia5d regulates a new fibroblast-like synoviocyte invasion-associated gene expression signature. Arthritis Res. Ther. 10, R92 (2008).
18. Oke, V. et al. High Ro52 expression in spontaneous and UV-induced cutaneous inflammation. J. Invest. Dermatol. 129, 2000-2010 (2009).
19. Carthagena, L. et al. Human TRIM gene expression in response to interferons. PLoS ONE 4, e4894 (2009).
20. Rajsbaum, R., Stoye, J. P. & O'Garra, A. Type I interferon-dependent and-independent expression of tripartite motif proteins in immune cells. Eur. J. Immunol. 38, 619-630 (2008).
21. Scofield, R. H., Farris, A. D., Horsfall, A. C. & Harley, J. B. Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins. Arthritis Rheum. 42, 199-209 (1999). (Pubitemid 29072836)
22. Kong, H. J. et al. Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J. Immunol. 179, 26-30 (2007).
23. Higgs, R. et al. The E3 ubiquitin ligase Ro52 negatively regulates IFN-β production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J. Immunol. 181, 1780-1786 (2008).
24. Yang, K. et al. TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. J. Immunol. 182, 3782-3792 (2009).
25. Young, J. A. et al. Fas-associated death domain (FADD) and the E3 ubiquitin-protein ligase TRIM21 interact to negatively regulate virus-induced interferon production. J. Biol. Chem. 286, 6521-6531 (2011).
26. Espinosa, A. et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J. Exp. Med. 206, 1661-1671 (2009).
27. Yoshimi, R. et al. Gene disruption study reveals a nonredundant role for TRIM21/Ro52 in NF-κB-dependent cytokine expression in fibroblasts. J. Immunol. 182, 7527-7538 (2009).
28. Higgs, R. et al. Self protection from anti-viral responses-Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-like receptors. PLoS ONE 5, e11776 (2010).
29. Ozato, K. et al. Comment on "Gene disruption study reveals a nonredundant role for TRIM21/Ro52 in NF-κB-dependent cytokine expression in fibroblasts". J. Immunol. 183, 7619 (2009).
30. Espinosa, A., Brauner, S., Ambrosi, A., Kuchroo, V. K. & Wahren-Herlenius, M. Response to comment on "Gene disruption study reveals a nonredundant role for TRIM21/Ro52 in NF-κB-dependent cytokine expression in fibroblasts". J. Immunol. 183, 7620-7621 (2009).
31. Mallery, D. L. et al. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc. Natl Acad. Sci. USA 107, 19985-19990 (2010).
32. Beer, H. D. et al. The estrogen-responsive B box protein: a novel regulator of keratinocyte differentiation. J. Biol. Chem. 277, 20740-20749 (2002).
33. Cheung, B. B. et al. The estrogen-responsive B box protein is a novel regulator of the retinoid signal. J. Biol. Chem. 281, 18246-18256 (2006). (Pubitemid 44035625)
34. Marshall, G. M. et al. TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells. Oncogene 29, 6172-6183 (2010).
35. Vossenaar, E. R. et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res. Ther. 6, R142-R150 (2004).
36. Van Steendam, K., Tilleman, K. & Deforce, D. The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis. Rheumatology 50, 830-837 (2011).
37. Dejaco, C. et al. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res. Ther. 8, R119 (2006).
38. Mor-Vaknin, N., Punturieri, A., Sitwala, K. & Markovitz, D. M. Vimentin is secreted by activated macrophages. Nature Cell Biol. 5, 59-63 (2003). (Pubitemid 36054330)
39. Kivity, S., Agmon-Levin, N., Blank, M. & Shoenfeld, Y. Infections and autoimmunity-friends or foes? Trends Immunol. 30, 409-414 (2009).
40. Uchil, P. D., Quinlan, B. D., Chan, W. T., Luna, J. M. & Mothes, W. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog. 4, e16 (2008).
41. Balada, E., Vilardell-Tarres, M. & Ordi-Ros, J. Implication of human endogenous retroviruses in the development of autoimmune diseases. Int. Rev. Immunol. 29, 351-370 (2010).
42. Baudino, L., Yoshinobu, K., Dunand-Sauthier, I., Evans, L. H. & Izui, S. TLR-mediated up-regulation of serum retroviral gp70 is controlled by the Sgp loci of lupus-prone mice. J. Autoimmun. 35, 153-159 (2010).
43. Baudino, L., Yoshinobu, K., Morito, N., Santiago-Raber, M. L. & Izui, S. Role of endogenous retroviruses in murine SLE. Autoimmun. Rev. 10, 27-34 (2010).
44. Song, B. TRIM5α. Curr. Top. Microbiol. Immunol. 339, 47-66 (2009).
45. Sebastian, S. & Luban, J. TRIM5α selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2, 40 (2005).
46. Nexo, B. A. et al. The etiology of multiple sclerosis: genetic evidence for the involvement of the human endogenous retrovirus HERV-Fc1. PLoS ONE 6, e16652 (2011).
47. Wolf, D. & Goff, S. P. TRIM28 mediates primer binding site-targeted silencing of murine leukemia virus in embryonic cells. Cell 131, 46-57 (2007). (Pubitemid 47498526)
48. Wolf, D. & Goff, S. P. Embryonic stem cells use ZFP809 to silence retroviral DNAs. Nature 458, 1201-1204 (2009).
49. Gack, M. U. et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446, 916-920 (2007). (Pubitemid 46633167)
50. Zeng, W. et al. Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell 141, 315-330 (2010).
51. Wang, P. et al. Caspase-12 controls West Nile virus infection via the viral RNA receptor RIG-I. Nature Immunol. 11, 912-919 (2010).
52. Tsuchida, T. et al. The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. Immunity 33, 765-776 (2010).
53. Zha, J. et al. The Ret finger protein inhibits signaling mediated by the noncanonical and canonical IκB kinase family members. J. Immunol. 176, 1072-1080 (2006). (Pubitemid 43099708)
54. Baranzini, S. E. The genetics of autoimmune diseases: a networked perspective. Curr. Opin. Immunol. 21, 596-605 (2009).
55. Noguchi, K. et al. TRIM40 promotes neddylation of IKKγ and is downregulated in gastrointestinal cancers. Carcinogenesis 32, 995-1004 (2011).
56. Arimoto, K. et al. Polyubiquitin conjugation to NEMO by triparite motif protein 23 (TRIM23) is critical in antiviral defense. Proc. Natl Acad. Sci. USA 107, 15856-15861 (2010).
57. Poole, E. et al. Identification of TRIM23 as a cofactor involved in the regulation of NF-κB by human cytomegalovirus. J. Virol. 83, 3581-3590 (2009).
58. Nishibori, T., Tanabe, Y., Su, L. & David, M. Impaired development of CD4+ CD25+ regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease. J. Exp. Med. 199, 25-34 (2004). (Pubitemid 38076475)
59. Bettelli, E. et al. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 200, 79-87 (2004). (Pubitemid 38924730)
60. Sigurdsson, S. et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76, 528-537 (2005). (Pubitemid 40250533)
61. Graham, R. R. et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nature Genet. 38, 550-555 (2006).
62. Salloum, R. et al. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-α activity in lupus patients. Arthritis Rheum. 62, 553-561 (2010).
63. Feng, D. et al. Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum. 62, 562-573 (2010).
64. Kamitani, S. et al. KAP1 regulates type I interferon/STAT1-mediated IRF-1 gene expression. Biochem. Biophys. Res. Commun. 370, 366-370 (2008).
65. Tsuruma, R. et al. Physical and functional interactions between STAT3 and KAP1. Oncogene 27, 3054-3059 (2008). (Pubitemid 351668002)
66. Wada, K., Niida, M., Tanaka, M. & Kamitani, T. Ro52-mediated monoubiquitination of IKKβ down-regulates NF-κB signalling. J. Biochem. 146, 821-832 (2009).
67. Niida, M., Tanaka, M. & Kamitani, T. Downregulation of active IKKβ by Ro52-mediated autophagy. Mol. Immunol. 47, 2378-2387 (2010).
68. Everett, R. D. & Chelbi-Alix, M. K. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89, 819-830 (2007). (Pubitemid 47008945)
69. El Bougrini, J., Dianoux, L. & Chelbi-Alix, M. K. PML positively regulates interferon γ signaling. Biochimie 93, 389-398 (2011).
70. Wu, W. S., Xu, Z. X. & Chang, K. S. The promyelocytic leukemia protein represses A20-mediated transcription. J. Biol. Chem. 277, 31734-31739 (2002).
71. Wu, W. S. et al. Promyelocytic leukemia protein sensitizes tumor necrosis factor α-induced apoptosis by inhibiting the NF-κB survival pathway. J. Biol. Chem. 278, 12294-12304 (2003).
72. Xu, D. et al. Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity. Immunity 30, 802-816 (2009).
73. Stinton, L. M., Swain, M., Myers, R. P., Shaheen, A. A. & Fritzler, M. J. Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis. Clin. Exp. Immunol. 163, 147-156 (2011).
74. Fracchia, M. et al. Serum interferon γ in primary biliary cirrhosis: effect of ursodeoxycholic acid and prednisone therapy alone and in combination. Eur. J. Gastroenterol. Hepatol. 12, 463-468 (2000). (Pubitemid 30218954)
75. Okumura, F., Matsunaga, Y., Katayama, Y., Nakayama, K. I. & Hatakeyama, S. TRIM8 modulates STAT3 activity through negative regulation of PIAS3. J. Cell Sci. 123, 2238-2245 (2010).
76. Okumura, F., Okumura, A. J., Matsumoto, M., Nakayama, K. I. & Hatakeyama, S. TRIM8 regulates Nanog via Hsp90β-medicated nuclear translocation of STAT3 in embryonic stem cells. Biochim. Biophys. Acta 2 Jun 2011 (doi:10.1016/j.bbamcr.2011.05.013).
77. Ben-Zvi, I. & Livneh, A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nature Rev. Rheumatol. 7, 105-112 (2011).
78. Shaw, P. J., McDermott, M. F. & Kanneganti, T. D. Inflammasomes and autoimmunity. Trends Mol. Med. 17, 57-64 (2011).
79. Richards, N. et al. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J. Biol. Chem. 276, 39320-39329 (2001).
80. Yu, J. W. et al. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol. Cell 28, 214-227 (2007).
81. Papin, S. et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1β processing. Cell Death Differ. 14, 1457-1466 (2007). (Pubitemid 47096500)
82. Yu, J. W. et al. Cryopyrin and pyrin activate caspase-1, but not NF-κB, via ASC oligomerization. Cell Death Differ. 13, 236-249 (2006).
83. Chae, J. J. et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-κB through its N-terminal fragment. Blood 112, 1794-1803 (2008).
84. Chae, J. J. et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc. Natl Acad. Sci. USA 103, 9982-9987 (2006). (Pubitemid 43993609)
85. Unal, A., Dursun, A., Emre, U., Tascilar, N. F. & Ankarali, H. Evaluation of common mutations in the Mediterranean fever gene in multiple sclerosis patients: is it a susceptibility gene? J. Neurol. Sci. 294, 38-42 (2010).
86. Yahalom, G. et al. Familial Mediterranean fever (FMF) and multiple sclerosis: an association study in one of the world's largest FMF cohorts. Eur. J. Neurol. 8 Feb 2011 (doi:10.1111/j.1468-1331.2011.03356.x).
87. Merrill, J. E. Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome. J. Immunother. 12, 167-170 (1992).
88. Shoham, N. G. et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl Acad. Sci. USA 100, 13501-13506 (2003). (Pubitemid 37444771)
89. Munding, C. et al. The estrogen-responsive B box protein: a novel enhancer of interleukin-1β secretion. Cell Death Differ. 13, 1938-1949 (2006). (Pubitemid 44542406)
90. Hu, Y. et al. Tripartite-motif protein 30 negatively regulates NLRP3 inflammasome activation by modulating reactive oxygen species production. J. Immunol. 185, 7699-7705 (2010).
91. Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221-225 (2011).
92. Shi, M. et al. TRIM30α negatively regulates TLR-mediated NF-κB activation by targeting TAB2 and TAB3 for degradation. Nature Immunol. 9, 369-377 (2008). (Pubitemid 351405106)
93. Tareen, S. U. & Emerman, M. Human Trim5α has additional activities that are uncoupled from retroviral capsid recognition. Virology 409, 113-120 (2011).
94. Pertel, T. et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472, 361-365 (2011).
95. Reymond, A. et al. The tripartite motif family identifies cell compartments. EMBO J. 20, 2140-2151 (2001). (Pubitemid 32410584)
96. Asaoka, K. et al. A retrovirus restriction factor TRIM5α is transcriptionally regulated by interferons. Biochem. Biophys. Res. Commun. 338, 1950-1956 (2005). (Pubitemid 41643112)
97. Chelbi-Alix, M. K. et al. Induction of the PML protein by interferons in normal and APL cells. Leukemia 9, 2027-2033 (1995). (Pubitemid 26023786)
98. Strandberg, L. et al. Interferon-α induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J. Clin. Immunol. 28, 220-231 (2008).
99. Casciola-Rosen, L. A., Anhalt, G. & Rosen, A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179, 1317-1330 (1994). (Pubitemid 24091790)
100. Ohlsson, M., Jonsson, R. & Brokstad, K. A. Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjogren's syndrome. Scand. J. Immunol. 56, 456-469 (2002). (Pubitemid 35373682)
101. Chae, J. J. et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol. Cell 11, 591-604 (2003). (Pubitemid 36385116)
102. Hoshino, K. et al. Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis. Rheumatology 49, 726-1733 (2010).
103. Randrianarison-Huetz, V. et al. Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-β signaling at the bipotent erythro-megakaryocytic progenitor stage. Blood 115, 2784-2795 (2010).
104. Billaut-Mulot, O. et al. SS-56, a novel cellular target of autoantibody responses in Sjogren syndrome and systemic lupus erythematosus. J. Clin. Invest. 108, 861-869 (2001). (Pubitemid 32880295)